Observational studyFrontiers in endocrinology2026
Non-invasive risk stratification of metabolic dysfunction-associated steatotic liver disease and liver fibrosis in adults with type 1 diabetes.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging comorbidity among patients with type 1 diabetes (T1D) that can potentially increase liver and cardiovascular outcomes. The aim of this study was to evaluate hepatic steatosis and to characterize non-invasive markers of MASLD and liver fibrosis risk in adults with T1D. Methods: A cross-sectional, observational, single-center study was conducted from 2023-2024. The sample was adults with T1D at a tertiary hospital in Mexico. We recorded clinical, body-composition, and laboratory data. Hepatic steatosis was assessed by ultrasound, and non-invasive indices [Hepatic steatosis index (HSI), fatty liver index (FLI), and Fibrosis-4 (FIB-4)] and 2D shear-wave elastography (2D-SWE) were used to stratify the risk of MASLD and liver fibrosis. Bivariable and correlation analyses were performed. Results: Sixty-five adults were included (61.5% women; age 34 ± 10 years; T1D duration 20 [15-28] years; dyslipidemia 45%; overweight/obesity 51%; HbA1c 8.8 ± 2.0%. Ultrasound-compatible hepatic steatosis was observed in 25% (n=16). Noninvasive indices identified a higher proportion of individuals at increased risk for MASLD and fibrosis. HSI flagged 52% at risk and FLI 25% at high risk. Mean FIB-4 was 0.64 ± 0.36; 20% had fibrosis stage 2-3 and one stage 4-5. Elastography stiffness averaged 5.9 ± 0.69 kPa; 5% ≥7-8 kPa. MASLD was associated with higher stiffness, FIB-4, AST and lower platelets (all p<0.05; HSI p=0.06). Visceral fat correlated with HSI (r=0.525) and FLI (r=0.505) and inversely with FIB-4 (r=-0.261). Conclusions: Non-invasive tools allow the identification of adults with T1D at increased risk for steatotic liver disease and fibrosis; however, these findings should be interpreted as risk stratification rather than definitive diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.